Novo’s Wegovy, Lilly’s Zepbound Touted as First-Line Obesity Drugs

n-tv.de

Lean Right

Factuality

Ownership

The European Association for Obesity Research recommends that treatment with the active substances semaglutide and tirzepatide be the standard for the treatment of obesity. Although the means are expensive, the subsequent costs of the disease would be significantly higher.

Salzburger Nachrichten

Factuality

Ownership

The weight loss syringes of Novo Nordisk and Eli Lilly should be the standard therapy in the treatment of obesity, according to the recommendation of a leading European medical association. The active ingredients semaglutide, which is contained in the Novo-mediums Wegovy and Ozempic, and Tirzepatide of Lilly, which is sold as Zepbound and Mounjaro, are so effective that they should be the first choice in almost all cases if there is a need for s…

www.ertnews.gr

Factuality

Ownership

The new drugs "semaglutide" and "tirzepatide" are those proposed by the companies "Novo" and "Lilly" for the treatment of obesity, although their long-term use can cause side effects such as nutritional deficiencies, reduced bone and muscle mass, frequent discontinuation of the diet and weight regain, as well as high purchase costs.